Journal of glaucoma · 2026
Intraoperative Triamcinolone Acetonide Injection During Ahmed Glaucoma Valve Surgery Suppresses the Occurrence of the Postoperative Hypertensive Phase.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hirota Akira, Asaoka Satoko, Kuroda Kohei, Hayashi Yusuke, Asada Yosuke, Iwamoto Satoshi, Chihara Etsuo, Sasaki Hidenori, Aso Hiroshi, Saeki Tadashiro, Yamagami Satoru, Matsuda Akira
Аннотация
PRCIS: Intraoperative sub-plate injection of triamcinolone acetonide during Ahmed glaucoma valve implantation markedly reduced the incidence of the postoperative hypertensive phase without increasing complications.
PURPOSE: The objective of this study was to evaluate whether intraoperative sub-plate injection of triamcinolone acetonide (TA) during Ahmed glaucoma valve (AGV) implantation reduces postoperative hypertensive phase (HP) incidence.
PATIENTS AND METHODS: We included 182 eyes from 182 patients who underwent AGV implantation between June 2017 and December 2023 at five institutions in Japan and were followed for a minimum of 3 months. The eyes were divided into two groups: 103 eyes received intraoperative sub-plate TA injection (TA group), and 79 eyes did not (non-TA group). The HP was defined as an initial intraocular pressure reduction to ≤22 mm Hg within 1 week postoperatively, followed by an increase to >21 mm Hg on two or more occasions within 3 months. Fisher's exact test,nonparametric tests, and multivariate logistic regression were used for statistical analyses.
RESULTS: HP occurred in 8 (7.8%) and 28 (35.4%) eyes in TA and non-TA groups, respectively (P<0.0001). Among the eyes with anterior chamber tube placement, no cases of HP were observed in the TA group, whereas 8 cases occurred in the non-TA group (P<0.0001). In pars plana cases, HP developed in 8 and 20 eyes in the TA and non-TA groups, respectively (P=0.016). Multivariate logistic regression analysis identified the absence of intraoperative TA injection as an independent risk factor for the HP (odds ratio: 0.16, P<0.0001).
CONCLUSIONS: Intraoperative sub-plate TA injection may be associated with a reduced incidence of postoperative HP after AGV implantation.
PURPOSE: The objective of this study was to evaluate whether intraoperative sub-plate injection of triamcinolone acetonide (TA) during Ahmed glaucoma valve (AGV) implantation reduces postoperative hypertensive phase (HP) incidence.
PATIENTS AND METHODS: We included 182 eyes from 182 patients who underwent AGV implantation between June 2017 and December 2023 at five institutions in Japan and were followed for a minimum of 3 months. The eyes were divided into two groups: 103 eyes received intraoperative sub-plate TA injection (TA group), and 79 eyes did not (non-TA group). The HP was defined as an initial intraocular pressure reduction to ≤22 mm Hg within 1 week postoperatively, followed by an increase to >21 mm Hg on two or more occasions within 3 months. Fisher's exact test,nonparametric tests, and multivariate logistic regression were used for statistical analyses.
RESULTS: HP occurred in 8 (7.8%) and 28 (35.4%) eyes in TA and non-TA groups, respectively (P<0.0001). Among the eyes with anterior chamber tube placement, no cases of HP were observed in the TA group, whereas 8 cases occurred in the non-TA group (P<0.0001). In pars plana cases, HP developed in 8 and 20 eyes in the TA and non-TA groups, respectively (P=0.016). Multivariate logistic regression analysis identified the absence of intraoperative TA injection as an independent risk factor for the HP (odds ratio: 0.16, P<0.0001).
CONCLUSIONS: Intraoperative sub-plate TA injection may be associated with a reduced incidence of postoperative HP after AGV implantation.